{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:41:54Z","timestamp":1775094114611,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bone.2010.06.029","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T08:41:12Z","timestamp":1278405672000},"page":"121-128","source":"Crossref","is-referenced-by-count":45,"title":["Tumor\u2013host cell interactions in the bone disease of myeloma"],"prefix":"10.1016","volume":"48","author":[{"given":"Jessica A.","family":"Fowler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2010.06.029_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bone.2010.06.029_bb0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.06.029_bb0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM197404182901601","article-title":"Bone-resorbing activity in supernatants from lymphoid cell lines","volume":"290","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/8756-3282(94)90890-7","article-title":"Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma","volume":"15","author":"Roux","year":"1994","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.06.029_bb0035","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0040","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.bone.2010.06.029_bb0045","article-title":"Osteoprotegerin is a soluble decoy receptor for TRAIL\/Apo2L and can function as a paracrine survival factor for human myeloma cells","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1200\/JCO.2002.20.1.353","article-title":"Human bone marrow myeloma cells express RANKL","volume":"20","author":"Sezer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2010.06.029_bb0055","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0060","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment:Myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0065","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-\uf06bB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0070","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/0008-5472.CAN-06-1287","article-title":"An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma","volume":"67","author":"Heath","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0080","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/sj.leu.2404814","article-title":"A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer","volume":"21","author":"Rabin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2010.06.029_bb0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exphem.2004.01.006","article-title":"Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts","volume":"32","author":"Doran","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0090","first-page":"2572","article-title":"Terapeutic efficacy of soluble receptor activator of nuclear factor kB-Ig Fc fusion protein in suppressing bone resorption and hypercalcaemia in a model of humoral hypercalcaemia of malignancy","volume":"61","author":"Oyayobi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0105","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.bone.2010.06.029_bb0125","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","article-title":"MIP-1{alpha} (CCL3) is a downstream target of FGFR3 and RAS\/MAPK signaling in multiple myeloma","volume":"108","author":"Masih-Khan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0130","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0135","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0140","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0145","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V94.11.3883","article-title":"Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease","volume":"94","author":"Hjertner","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11899-009-0015-4","article-title":"The role of bisphosphonates in multiple myeloma","volume":"4","author":"Levy","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bone.2010.06.029_bb0155","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/bjc.1986.136","article-title":"Importance of quantitative histology of bone changes in monoclonal gammopathy","volume":"53","author":"Bataille","year":"1986","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2010.06.029_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9","article-title":"Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications","volume":"66","author":"Bataille","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.06.029_bb0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1302\/0301-620X.71B2.2925748","article-title":"Does myeloma secrete an osteoblast inhibiting factor?","volume":"71","author":"Evans","year":"1989","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.bone.2010.06.029_bb0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.06.029_bb0175","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.1990.tb07904.x","article-title":"Osteoblast stimulation in multiple myeloma lacking lytic bone lesions","volume":"76","author":"Bataille","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0180","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1359\/jbmr.2003.18.6.1088","article-title":"RANKL expression is related to the differentiation state of human osteoblasts","volume":"18","author":"Atkins","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0185","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.2007.06871.x","article-title":"Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis","volume":"140","author":"Haaber","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0195","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0200","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bone.2010.06.029_bb0205","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0210","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","article-title":"Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment","volume":"67","author":"Giuliani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0215","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.bone.2010.06.029_bb0220","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/10428190701593644","article-title":"Mesenchymal stem cell abnormalities in patients with multiple myeloma","volume":"48","author":"Garderet","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bone.2010.06.029_bb0225","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2010.06.029_bb0230","article-title":"Myeloma-associated fibroblasts suppress osteoblasts in vivo independent of tumor presence","volume":"24","author":"Fowler","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0235","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0240","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0250","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"Sukhdeo","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.06.029_bb0255","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0260","series-title":"Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease. VIIIth International Meeting on Cancer-Induced Bone Disease","author":"Abdul","year":"2009"},{"key":"10.1016\/j.bone.2010.06.029_bb0265","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0270","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bone.2010.06.029_bb0275","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.onc.1206239","article-title":"Wnt signaling in B-cell neoplasia","volume":"22","author":"Qiang","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bone.2010.06.029_bb0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0285","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1158\/1078-0432.CCR-08-0219","article-title":"Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells","volume":"14","author":"Silvestris","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0290","doi-asserted-by":"crossref","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107: 5124-9","DOI":"10.1073\/pnas.0911929107"},{"key":"10.1016\/j.bone.2010.06.029_bb0295","unstructured":"Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P. Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. J Bone Miner Res."},{"key":"10.1016\/j.bone.2010.06.029_bb0300","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","article-title":"Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma","volume":"91","author":"Seidel","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0305","doi-asserted-by":"crossref","unstructured":"Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, Jiri V, Roman H. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 84: 332-6.","DOI":"10.1111\/j.1600-0609.2009.01396.x"},{"key":"10.1016\/j.bone.2010.06.029_bb0310","doi-asserted-by":"crossref","unstructured":"Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 57: 29-34.","DOI":"10.4149\/neo_2010_01_029"},{"key":"10.1016\/j.bone.2010.06.029_bb0315","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2141.2004.05299.x","article-title":"Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival","volume":"128","author":"Andersen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2006.11.024","article-title":"Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma","volume":"379","author":"Alexandrakis","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bone.2010.06.029_bb0325","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0330","doi-asserted-by":"crossref","unstructured":"Takeuchi K, Abe M, Hiasa M, Oda A, Amou H, Kido S, Harada T, Tanaka O, Miki H, Nakamura S, Nakano A, Kagawa K, Yata K, Ozaki S, Matsumoto T. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE 5: e9870.","DOI":"10.1371\/journal.pone.0009870"},{"key":"10.1016\/j.bone.2010.06.029_bb0335","doi-asserted-by":"crossref","unstructured":"Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46: 1082-8.","DOI":"10.1016\/j.bone.2010.01.370"},{"key":"10.1016\/j.bone.2010.06.029_bb0340","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.06.029_bb0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0350","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.06.029_bb0355","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0360","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0365","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2010.06.029_bb0370","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2010.06.029_bb0375","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.leukres.2008.07.028","article-title":"Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6","volume":"33","author":"Hongming","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0380","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","author":"Pennisi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0385","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0390","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ajh.21374","article-title":"Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo","volume":"84","author":"Edwards","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0395","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2010.06.029_bb0400","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0405","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1532\/IJH97.07030","article-title":"Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma","volume":"86","author":"Ozaki","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0410","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0415","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3816\/CLM.2007.n.045","article-title":"Bortezomib inhibits osteoclast activity in patients with multiple myeloma","volume":"7","author":"Uy","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.bone.2010.06.029_bb0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2010.06.029_bb0425","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1242\/dmm.003160","article-title":"A murine model of myeloma that allows genetic manipulation of the host microenvironment","volume":"2","author":"Fowler","year":"2009","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.bone.2010.06.029_bb0430","doi-asserted-by":"crossref","unstructured":"Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38: 141-53","DOI":"10.1016\/j.exphem.2009.11.009"},{"key":"10.1016\/j.bone.2010.06.029_bb0435","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.060610","article-title":"Role of IGF-I signaling in regulating osteoclastogenesis","volume":"21","author":"Wang","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0440","doi-asserted-by":"crossref","unstructured":"De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115: 2430-40.","DOI":"10.1182\/blood-2009-07-232801"},{"key":"10.1016\/j.bone.2010.06.029_bb0445","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell\u2013cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0450","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease","volume":"114","author":"Kukreja","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0455","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.06.029_bb0460","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2010.06.029_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1016-8478(23)12997-9","article-title":"Osteoimmunology: interactions of the immune and skeletal systems","volume":"17","author":"Rho","year":"2004","journal-title":"Mol Cells"},{"key":"10.1016\/j.bone.2010.06.029_bb0470","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1359-6101(03)00027-3","article-title":"Biology of the TRANCE axis","volume":"14","author":"Walsh","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bone.2010.06.029_bb0475","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00109-004-0612-6","article-title":"Mechanistic insight into osteoclast differentiation in osteoimmunology","volume":"83","author":"Takayanagi","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0480","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","article-title":"T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction","volume":"104","author":"Colucci","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0485","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ni1460","article-title":"Reis e Sousa C. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17","volume":"8","author":"LeibundGut-Landmann","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0490","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ni1430","article-title":"CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE","volume":"8","author":"Bailey","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0495","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2010.06.029_bb0500","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejim.2006.02.012","article-title":"Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma","volume":"17","author":"Alexandrakis","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0505","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2010.06.029_bb0510","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.06.029_bb0515","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0520","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-0-387-72005-0_22","article-title":"Myeloid-derived suppressor cells","volume":"601","author":"Nagaraj","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bone.2010.06.029_bb0525","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4049\/jimmunol.170.1.270","article-title":"IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice","volume":"170","author":"Bronte","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0530","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4049\/jimmunol.165.2.779","article-title":"Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3\/CD28 costimulation","volume":"165","author":"Kusmartsev","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0535","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"Bronte","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0540","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.bone.2010.06.029_bb0545","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1172\/JCI29906","article-title":"Myeloid suppressor cells regulate the adaptive immune response to cancer","volume":"116","author":"Frey","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.06.029_bb0550","first-page":"S2","article-title":"Osteoclasts in myeloma are derived from Gr-1+CDllb+mononuclear cells of the bone marrow niche","volume":"22","author":"Zhuang","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.06.029_bb0555","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V112.11.736.736","article-title":"Osteoclasts in myeloma are derived from Gr-1+CD11b+myeloid immune suppressor cells of the bone marrow niche in vivo","volume":"112","author":"Zhuang","year":"2008","journal-title":"Blood"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210013438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210013438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T17:04:55Z","timestamp":1740243895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210013438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S8756328210013438"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.06.029","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}